-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Barchart·08/06/2026 15:05:00
Listen to the news

First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) 
Phase 3 ACCOMPLISH program for chronic weight management

Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.